KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kailera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.43+0.18 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 26, 2026 | During market hours | – | – | – |
Press releases
Announcements Kailera Therapeutics filed with the SEC
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Results of operations · EX-99.1 to Form 8-K